Vincristine Therapy of Idiopathic and Secondary Thrombocytopenias

Yeon S. Ahn, William J. Harrington, Robert C. Seelman, Charles S. Eytel

Research output: Contribution to journalArticlepeer-review

144 Scopus citations


Idiopathic thrombocytopenia refractory to glucocorticoids and splenectomy remains a serious problem. Prompt benefit was obtained from vincristine in 6 of 7 patients not splenectomized who were refractory to glucocorticoids and in 9 of 13 patients refractory to both glucocorticoids and splenectomy. Five of the 9 were also refractory to cyclophosphamide or azathioprine or both. Vincristine also benefited 10 of 10 patients with thrombocytopenia and serologic evidence of lupus erythematosus or its variants, some patients with various forms of bone marrow insufficiency, and 3 of 3 with thrombocytopenia due to lymphocytic leukemia. Vincristine accordingly appears to be indicated in the management of several forms of thrombocytopenia refractory to splenectomy and glucocorticoids. Its value as compared to vinblastine, azathioprine, and cyclophosphamide remains to be determined.

Original languageEnglish (US)
Pages (from-to)376-380
Number of pages5
JournalNew England Journal of Medicine
Issue number8
StatePublished - Aug 22 1974

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Vincristine Therapy of Idiopathic and Secondary Thrombocytopenias'. Together they form a unique fingerprint.

Cite this